{"id":474455,"date":"2020-03-17T14:22:01","date_gmt":"2020-03-17T14:22:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=474455"},"modified":"2020-03-17T14:22:01","modified_gmt":"2020-03-17T14:22:01","slug":"blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_474455.html","title":{"rendered":"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Blastic<\/a><\/div>\n

DelveInsight has launched a new report on BPDCN Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “BPDCN<\/strong> Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the BPDCN<\/strong><\/em>, historical and forecasted epidemiology as well as the BPDCN<\/strong><\/em> market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/em><\/p>\n

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy of the bone marrow and blood that can affect other organs such as the lymph nodes, spleen, central nervous system, and skin. In fact, skin lesions are present in most patients with BPDCN. These skin lesions are often a deep purple color, and patients often develop multiple lesions. More men than women are diagnosed with BPDCN (~3:1 ratio), and it is most common in patients age 60 years and older. Although BPDCN occurs more frequently in the elderly, the tumor may occur in patients of any age, including pediatric patients. Previously referred to as blastic NK cell leukemia and agranular CD4+\/CD56+ hematodermic neoplasm, BPDCN was officially named by the World Health Organization in 2008. BPDCN can also evolve from prior myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML), so patients with those diseases and skin lesions should be specifically evaluated for BPDCN.<\/p>\n

 <\/strong><\/p>\n

\"\"<\/strong><\/p>\n

 <\/p>\n

 <\/p>\n

Request for:-  <\/strong>BPDCN free sample page<\/a><\/p>\n

 <\/strong><\/p>\n

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)  Epidemiology  <\/strong><\/p>\n

The Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) epidemiology division provide insights about historical and current Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.<\/p>\n

 <\/strong><\/p>\n

Some of the Report Key facts:-<\/strong><\/p>\n

1. <\/strong>According to a study by Petrella T et al., titled, “Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review”, BPDCN has been described in all age groups but is most common in adults. BPDCN represent 0.7 percent of primary cutaneous skin lymphomas.<\/p>\n

2<\/strong>. As per a study published by Aurelia Meloni et al., titled, “Review on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), with data on clinics, and the genes involved”, the incidence of this neoplasm accounts for 0.4% of all hematologic neoplasms, 0.7% of the primary cutaneous lymphomas, and less than 1% of all acute leukemias (Facchetti et al., 2008; Riaz et al., 2014; Rossi et al., 2006; Pagano et al., 2013)<\/p>\n

 <\/strong><\/p>\n

Report Key Benefits<\/strong><\/p>\n

1. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market report covers a descriptive overview and comprehensive insight of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) epidemiology Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

2. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market report provides insights on the current and emerging therapies. <\/p>\n

3. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market report offers a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

4. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Cold Agglutinin Disease market.<\/p>\n

 <\/p>\n

Some of the key companies working on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) that are given below-<\/strong><\/p>\n

    \n
  1. Stemline Therapeutics Inc.<\/li>\n
  2. Immunogen Pharma Co. <\/li>\n
  3. Cellectis Pharma Co. <\/li>\n<\/ol>\n

    Name of covered Drugs are given below. <\/strong><\/p>\n

      \n
    1. Elzonris (Tagraxofusp-erzs)<\/li>\n
    2. IMGN632<\/li>\n
    3. UCART123<\/li>\n<\/ol>\n

      Table of Contents<\/a><\/p>\n

      1. Key Insights<\/strong><\/p>\n

      2. Executive Summary of BPDCN<\/strong><\/strong><\/p>\n

      3. Competitive Intelligence Analysis for BPDCN<\/strong><\/strong><\/p>\n

      4. BPDCN<\/strong>: Market Overview at a Glance<\/strong><\/p>\n

      5. BPDCN<\/strong>: Disease Background and Overview<\/strong><\/p>\n

      6. Patient Journey<\/strong><\/p>\n

      7. Cold Agglutinin Disease (CAD) Epidemiology and Patient Population<\/strong><\/p>\n

      8. Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/p>\n

      9. Unmet Needs<\/strong><\/p>\n

      10. Key Endpoints of BPDCN<\/strong> Treatment<\/strong><\/p>\n

      11. Marketed Products<\/strong><\/p>\n

      12. Emerging Therapies<\/strong><\/p>\n

      13. BPDCN<\/strong>: Seven Major Market Analysis<\/strong><\/p>\n

      14. Attribute analysis<\/strong><\/p>\n

      15. 7MM: Market Outlook<\/strong><\/p>\n

      16. Access and Reimbursement Overview of BPDCN<\/strong><\/strong><\/p>\n

      17. KOL Views<\/strong><\/p>\n

      18. Market Drivers<\/strong><\/p>\n

      19. Market Barriers<\/strong><\/p>\n

      20. Appendix<\/strong><\/p>\n

      21. DelveInsight Capabilities<\/strong><\/p>\n

      22. Disclaimer<\/strong><\/p>\n

      23. About <\/strong>DelveInsight<\/a><\/p>\n

      Why should you buy this BPDCN market report? <\/strong><\/p>\n